Boston Scientific Corporation $BSX Shares Purchased by DekaBank Deutsche Girozentrale

Key Points

• DekaBank Deutsche Girozentrale increased its holdings in Boston Scientific by 8.7% in Q2, owning 1,844,793 shares valued at approximately $195.34 million.
• Boston Scientific reported Q2 earnings of $0.75 per share, exceeding analysts' expectations of $0.72, with revenue of $5.06 billion.
• Analysts have raised their price targets for Boston Scientific, with Raymond James setting a target of $124.00 and Oppenheimer raising theirs to $125.00.

DekaBank Deutsche Girozentrale boosted its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 8.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,844,793 shares of the medical equipment provider's stock after purchasing an additional 147,932 shares during the quarter. DekaBank Deutsche Girozentrale owned approximately 0.12% of Boston Scientific worth $195,338,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of BSX. Brighton Jones LLC boosted its holdings in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after acquiring an additional 226 shares during the period. GAMMA Investing LLC raised its stake in shares of Boston Scientific by 17.2% during the first quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider's stock valued at $2,578,000 after purchasing an additional 3,745 shares in the last quarter. Advisor Resource Council bought a new stake in shares of Boston Scientific during the first quarter valued at about $283,000. Intact Investment Management Inc. raised its stake in shares of Boston Scientific by 8.2% during the first quarter. Intact Investment Management Inc. now owns 5,300 shares of the medical equipment provider's stock valued at $535,000 after purchasing an additional 400 shares in the last quarter. Finally, Flagship Harbor Advisors LLC raised its stake in shares of Boston Scientific by 0.8% during the first quarter. Flagship Harbor Advisors LLC now owns 21,136 shares of the medical equipment provider's stock valued at $2,132,000 after purchasing an additional 160 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Trading Up 1.3%

Shares of BSX opened at $100.56 on Tuesday. The business's 50-day moving average price is $101.25 and its 200 day moving average price is $101.85. The stock has a market capitalization of $149.01 billion, a P/E ratio of 59.86, a P/E/G ratio of 2.39 and a beta of 0.61. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific's revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

BSX has been the topic of a number of recent analyst reports. Raymond James Financial lifted their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 24th. Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Barclays boosted their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an "overweight" rating in a research report on Thursday, October 2nd. Robert W. Baird boosted their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 1st. Finally, Wells Fargo & Company boosted their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $120.71.

Insider Buying and Selling

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares of the company's stock, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company's stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 174,214 shares of company stock worth $17,972,457. Company insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.